^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
Excerpt:
Patients were entered into this exploratory Phase II study with afatinib, which, among others, included a cohort of patients with HER2 kinase domain mutations...Five patients with a non-smoking history and metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified, three of which were evaluable for response.
DOI:
https://doi.org/10.1016/j.lungcan.2012.01.008
